DelveInsight's 'Hypogonadism - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hypogonadism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Hypogonadism epidemiology report gives a thorough understanding of the Hypogonadism by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hypogonadism in the US, Europe, and Japan. The report covers the detailed information of the Hypogonadism epidemiology scenario in seven major countries (US, EU5, and Japan).
The Hypogonadism epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Hypogonadism epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Hypogonadism epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Hypogonadism epidemiology covered in the report provides historical as well as forecasted Hypogonadism epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Hypogonadism report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Hypogonadism
3. Hypogonadism: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Hypogonadism Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Hypogonadism Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Hypogonadism Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Hypogonadism Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Hypogonadism Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Hypogonadism Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Hypogonadism Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Hypogonadism Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Hypogonadism Treatment and Management
6.2. Hypogonadism Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Hypogonadism Epidemiology in 7MM (2017-2030)
Table 2 Hypogonadism Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Hypogonadism Epidemiology in the United States (2017-2030)
Table 4 Hypogonadism Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Hypogonadism Epidemiology in Germany (2017-2030)
Table 6 Hypogonadism Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Hypogonadism Epidemiology in France (2017-2030)
Table 8 Hypogonadism Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Hypogonadism Epidemiology in Italy (2017-2030)
Table 10 Hypogonadism Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Hypogonadism Epidemiology in Spain (2017-2030)
Table 12 Hypogonadism Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Hypogonadism Epidemiology in the United Kingdom (2017-2030)
Table 14 Hypogonadism Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Hypogonadism Epidemiology in Japan (2017-2030)
Table 16 Hypogonadism Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Hypogonadism Epidemiology in 7MM (2017-2030)
Figure 2 Hypogonadism Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Hypogonadism Epidemiology in the United States (2017-2030)
Figure 4 Hypogonadism Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Hypogonadism Epidemiology in Germany (2017-2030)
Figure 6 Hypogonadism Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Hypogonadism Epidemiology in France (2017-2030)
Figure 8 Hypogonadism Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Hypogonadism Epidemiology in Italy (2017-2030)
Figure 10 Hypogonadism Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Hypogonadism Epidemiology in Spain (2017-2030)
Figure 12 Hypogonadism Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Hypogonadism Epidemiology in the United Kingdom (2017-2030)
Figure 14 Hypogonadism Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Hypogonadism Epidemiology in Japan (2017-2030)
Figure 16 Hypogonadism Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
